The revenue was beneath the estimates of Rs 1,410 crore (ET Now Ballot), damage by stiff competitors for the generic model of blockbuster most cancers drug Revlimid in its key North America market.
EBITDA for the quarter rose 15% YoY to Rs 2,351 crore within the reporting quarter.
“Development in Q2 was pushed by momentum in branded markets and regular contributions from the Nicotine Substitute Remedy (NRTJ portfolio, which helped offset the decline in US Lenalidomide gross sales,” stated GV Prasad, MD, Dr Reddy’s.
North America: Pricing strain drags development
North America, which contributes the most important share to Dr Reddy’s topline, remained below strain this quarter. Income from the area fell 13% YoY and 5% sequentially to Rs 3,240 crore, primarily as a result of value erosion in key merchandise like Lenalidomide.
The decline, nevertheless, was partly offset by new product launches and forex positive aspects. In the course of the quarter, the corporate launched seven new merchandise within the US and filed 5 new ANDAs with the USFDA, taking the overall pending approvals to 75 as of September 30, 2025.Extra to return…
based on season – the https://beiclo.net/it/progetti/atsrl/index.php/zahranini-kasina-jak-vybrat-to-prave-pro-vas/ still offers special “buffet desks and promotions, timed to a number of holidays.